GI Deals Are Up 1100% in 2026 — Here's the Data

Eleven gastroenterology deals closed between February 28 and August 28, 2026 — up from exactly zero in the prior six-month period. That's a 1100% increase, and it isn't a statistical anomaly. Two of the top five global pharma companies independently decided to make aggressive, multi-asset bets on the GI space within the same quarter. The gastroenterology deal trends in 2026 signal something structural: Big Pharma has concluded that the next wave of blockbuster anti-inflammatory and metabolic-GI assets will not come from internal pipelines, and they're paying up to fill the gap.

The Data — Gastroenterology Deal Activity, Period over Period

The dead zone in the back half of 2025 and early 2026 wasn't disinterest — it was a coiled spring. Pipeline readouts, regulatory signals, and competitive dynamics all converged in Q2 2026 to create a buying frenzy that compressed what would normally be 18–24 months of deal activity into roughly 90 days. If you're benchmarking gastroenterology licensing in 2026, the baseline has fundamentally reset. Use our Deal Benchmarks to see how current terms compare to prior cycles.

What's Driving the Trend

Pipeline convergence in integrin biology and IL-23. The scientific thesis that drove much of this activity centers on next-generation integrin inhibitors and gut-selective biologics. Morphic Therapeutic's oral integrin program — which Roche absorbed — represents a bet that the convenience advantages of oral dosing can peel share from injectable anti-TNFs and anti-integrins like vedolizumab. Prometheus's TL1A program, also swept up by Roche, targets a mechanism with Phase 2 data showing efficacy across IBD subtypes that has historically been difficult to treat. These aren't early-stage flyers. The assets that moved in Q2 2026 had clinical inflection points that de-risked them enough for large pharma to underwrite nine- and ten-figure deal values.

The GLP-1 halo effect on metabolic-GI. Lilly's move on Hanmi Pharm didn't happen in a vacuum. The GLP-1 revolution has expanded the commercial aperture for GI-adjacent indications — MASH, gastroparesis, and gut-brain axis disorders are now credible multi-billion-dollar markets. Lilly, already dominant in GLP-1 agonists, appears to be building a metabolic-GI franchise that extends beyond incretin mimetics. Hanmi's dual-agonist and long-acting peptide platforms fit that strategy precisely. The deal terms weren't disclosed, but Hanmi's prior licensing history (the Lilly-Hanmi insulin partnership, the Janssen deal) suggests this was not a small check.

Defensive positioning. Roche's three-deal sprint — Roivant, Prometheus, and Morphic in rapid succession — reads as a coordinated portfolio play, not three independent bids. AbbVie's Skyrizi and Rinvoq are projected to generate $27B+ combined by 2028 across immunology and GI. Johnson & Johnson's tremtumumab is advancing. Roche needed a GI franchise or risked being permanently locked out of a market that's consolidating fast. The urgency was strategic, not opportunistic.

Notable Deals

Roche's triple acquisition is the headline. Morphic (oral α4β7 integrin), Prometheus (anti-TL1A), and Roivant's GI assets all closed within three days of each other. That's not coincidence — it's a coordinated buildout of a GI immunology pipeline from scratch. Roche is essentially constructing a portfolio that covers three distinct mechanisms of action in IBD, positioning itself to run combination studies that no single-asset biotech could execute. The competitive moat, if Phase 3 data holds, would be significant.

The Hanmi-Lilly deals — listed twice, likely reflecting multi-component agreements signed across entities — point to Lilly's expanding definition of GI. Hanmi's peptide engineering platform has produced candidates across multiple metabolic and GI targets. The dual filing dates (June 5 and 7) suggest a master agreement with separate schedules for distinct assets or geographies. Lilly's gastroenterology licensing strategy in 2026 is clearly extensions of its metabolic franchise into gut-specific indications — a playbook that leverages existing commercial infrastructure and KOL relationships.

What This Means for BD Teams Right Now

If you're selling GI assets: this is the best market in a decade. Two major buyers are in active accumulation mode. Roche has publicly signaled its intent to build a GI franchise, and Lilly is expanding its metabolic-GI perimeter. AbbVie, J&J, and Pfizer have not yet made comparable moves — meaning there are at least three more potential acquirers who may feel compelled to act before the best assets are gone. Sellers with Phase 2 data in IBD, MASH, or functional GI disorders have leverage they didn't have 12 months ago. Use the Ambrosia calculator to model upfront-to-TDV ratios against the current market.

If you're buying: move now or pay more later. The window of negotiating leverage is closing. Each announced deal raises the comparable transaction set, which raises seller expectations. The Morphic precedent — an oral integrin inhibitor acquired pre-Phase 3 — has already reset valuation benchmarks for oral GI programs. Waiting for more clinical data sounds prudent until you realize that every positive readout also brings in two more bidders.

Deal structures to watch: Expect to see more opt-in structures with escalating economics, particularly for assets where the GI indication is one of several potential applications. Roche's Roivant deal likely includes indication-specific milestones that allow Roche to expand or contract its commitment based on data. For earlier-stage assets, co-development partnerships with shared risk and shared economics are gaining favor over traditional licensing — sellers want to retain upside in a market this hot, and buyers want to limit exposure until data matures. Review current structural norms on our Deal Benchmarks page.

Benchmark your deal against current market rates. Whether you're structuring a gastroenterology licensing deal in 2026 or evaluating inbound term sheets, the numbers have moved. Use the Ambrosia calculator to stress-test your assumptions against the latest comparable transactions and identify where your terms sit relative to the market.

Frequently Asked Questions

Why did gastroenterology deals go from zero to eleven in a single period?

The prior period's inactivity reflected a market waiting for clinical catalysts, not a lack of interest. Several Phase 2 readouts — particularly in anti-TL1A and oral integrin programs — landed in Q1-Q2 2026, providing the de-risking data that large pharma requires to commit capital. Roche's decision to execute three deals simultaneously created a competitive urgency that pulled forward other transactions. The 1100% increase is a compression of pent-up demand, not an organic acceleration curve.

Is the GI deal surge sustainable, or is this a one-time correction?

The underlying drivers — pipeline gaps at Top 20 pharma, looming LOE on legacy GI biologics, and the metabolic-GI convergence around GLP-1 biology — are structural, not cyclical. AbbVie's Humira biosimilar erosion is creating a $10B+ revenue gap that Skyrizi and Rinvoq can only partially fill in GI. At least 3–4 additional large pharma companies have identified GI as a strategic priority in their 2026 investor presentations but have not yet transacted. We expect deal volume to remain elevated through H1 2027, though the pace of Roche-scale portfolio acquisitions will slow as available targets thin out.

How should early-stage GI biotechs position themselves given these trends?

Focus on differentiated mechanism of action and oral or gut-selective delivery — those are the attributes that commanded premium economics in the 2026 deals. Biotechs with preclinical or Phase 1 GI assets should accelerate into proof-of-concept studies now, while buyer appetite is high and clinical milestones carry outsized valuation impact. Structure initial partnerships to preserve optionality across multiple GI indications; the Roche-Prometheus template suggests buyers are willing to pay for platform breadth, not just single-indication depth. Use Solidus to model how different deal structures affect your long-term economics.